Clinical trials: DENGUE
Dengue Fever
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults
The purpose of this study is to evaluate the safety and immune response of a naturally aged lot of tetravalent dengue vaccine (TDV) in healthy participants, aged 18 to 60 years, in non-endemic country(ies) for dengue.
- Trial name
- NCT03771963
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Dengue Fever
Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue
The purpose of this study is to investigate lot-to-lot consistency in terms of equivalence of the immune responses induced by 3 consecutive TDV lots in healthy participants aged 18 to 60 years in non-endemic country(ies) for…
- Trial name
- NCT03423173
- Testing
- TAK-003
- Where
- 14 sites in United States
- Volunteers
- 923 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Randomised Clinical Trial, Double Blind
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study. Forty-two flavivirus-naïve adults will be enrolled and will receive 3 administrations of VLPDEN-02 or control at days 0, 28, and 56.
- Conditions
- Randomised Clinical Trial, Double Blind, Dengue, Challenge Test
- Trial name
- NCT07831473
- Testing
- VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VLP Therapeutics
Dengue
Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
This study is being conducted to evaluate the safety and immunogenicity and antibody persistence of the candidate dengue vaccine.
- Trial name
- NCT02421367
- Where
- 2 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue
A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
This descriptive study will evaluate the safety and immunogenicity of 5 different formulations of the WRAIR dengue vaccine compared to a placebo.
- Trial name
- NCT00239577
- Testing
- Live attenuated tetravalent dengue vaccine
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue
A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan
The goal of this study is to determine the immunogenicity and safety of TV003(TetraVax-DV), a live attenuated tetravalent dengue vaccine candidate, in healthy human subjects in Taiwan
- Trial name
- NCT03485144
- Testing
- TV003
- Where
- Taiwan
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Dengue Virus Infection
Dengvaxia US Pregnancy Registry
The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy
- Trial name
- DNG00044 (NCT04486638)
- Testing
- Dengue Tetravalent Vaccine, Live
- Where
- Puerto Rico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue, Severe Dengue
Therapeutics for Moderate and Severe Dengue
The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection.
- Conditions
- Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases
- Trial name
- DEN-HOST (NCT07543458)
- Testing
- Dexamethasone, N-Acetylcysteine, Standard of care
- Where
- 18 sites in Bangladesh, Brazil and 8 more
- Volunteers
- 8,800 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Dengue
Effectiveness Evaluation of a Dengue Self-monitoring System
The goal of this clinical trial is to compare the effectiveness of a dengue self-monitoring system with standard care in reducing treatment delay among dengue patients receiving outpatient care.
- Trial name
- DeSMoS (NCT05688748)
- Testing
- Dengue self-monitoring system
- Where
- Malaysia
- Volunteers
- 37 people
- Sponsor
- University of Malaya
Dengue
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1.
- Trial name
- NCT07016321
- Testing
- Emetine Hydrochloride 6mg, Emetine Hydrochloride 12mg
- Where
- 2 sites in United States, Nepal
- Volunteers
- 600 people
- Sponsor
- Johns Hopkins University
Dengue Fever
Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore
The purpose of this study is to assess the post-vaccination neutralizing antibody response against each dengue serotype by vaccine group.
- Trial name
- NCT02425098
- Testing
- Takeda's Tetravalent Dengue Vaccine Candidate (TDV), Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
- Where
- 3 sites in Singapore
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Takeda
Viral Haemorrhagic Fever, Dengue Fever
Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms
To meet eligibility criteria, this study and informed consent of the syndrome of fever associated with bleeding of infectious diseases, severe patients to carry out multicenter, practical randomized controlled clinical research…
- Trial name
- NCT01973855
- Testing
- Western Medicine, TCM and Western Medicine
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Guangzhou 8th People's Hospital
Dengue, Chikungunya
Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa
The differential and systematic diagnosis of malaria, dengue and chikungunya in patients with fever (≥38.5°C) of undetermined etiology would allow the identification of infection by these pathogens and thus limit the…
- Conditions
- Dengue, Chikungunya, Malaria
- Trial name
- NCT06257810
- Testing
- VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG, Standard of care practices
- Where
- 3 sites in Burkina Faso, Côte d’Ivoire
- Volunteers
- 804 people
- Sponsor
- BioMérieux
Dengue
Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
The purpose of this study is to evaluate the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 (TetraVax-DV T005) in healthy adults, adolescents, and children in Dhaka…
- Trial name
- NCT02678455
- Testing
- TV005 vaccine
- Where
- Bangladesh
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tick-Borne Encephalitis
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
Tick-borne encephalitis (TBE) is a viral illness common in the Northern Hemisphere, especially Europe and Asia. TBE infection may lead to central nervous system problems and death.
- Trial name
- NCT00118924
- Testing
- LGT(TP21)/DEN4
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever, Fever
Study of Febrile Illness for Dengue-Endemic Areas in Latin America
The purpose of this study is to detect acute febrile episodes and dengue infection in five Latin American countries to assess dengue seroprevalence.
- Trial name
- NCT01293331
- Where
- 18 sites in Brazil, Colombia and 2 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue
Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
The purpose of this research study is to test a weakened form of an experimental dengue virus challenge at different doses to test if participants develop symptoms or circulating virus in the blood (called viremia).
- Trial name
- NCT05268302
- Testing
- Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Dengue, Dengue Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
The aim of this study is to evaluate the immunogenicity and safety of the CYD dengue vaccine in India adult subjects. Primary Objectives: To describe the neutralizing antibody response to each dengue virus serotype before the…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01550289
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
- Where
- 5 sites in India
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company